Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
464 stopped studies mapped to Malignant Central Nervous System Neoplasm and descendants · 90% state a reason
Over the 464 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or…(VISMOLY) | Phase 2 | terminated | Sep 18, 2013 | The Lymphoma Academic Research Organisation | lack of efficacy | Efficacy / futility |
| NCT01902771 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | Phase 1 | terminated | Jul 18, 2013 | Edward Ziga | Lack of Accrual | Enrollment / accrual |
| NCT00456612 | Radiosurgery for Glioblastoma Multiforme | Phase 1 / Phase 2 | terminated | Apr 5, 2007 | Beth Israel Deaconess Medical Center | Poor accrual | Enrollment / accrual |
| NCT01642823 | Cancer Biology of Retinoblastoma | — | terminated | Jul 17, 2012 | Stanford University | Logistics | Other (stated, no rule matched) |
| NCT00980551 | Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With…(RELRB1) | N/A | withdrawn | Sep 21, 2009 | Children's Hospital Medical Center, Cincinnati | No enrollment and competing studies | Enrollment / accrual |
| NCT00582608 | Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9 | N/A | terminated | Dec 28, 2007 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT00171938 | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent… | Phase 2 | terminated | Sep 15, 2005 | Novartis | not stated | Not stated |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | Phase 2 | withdrawn | Aug 23, 2016 | GenSpera, Inc. | This study has been withdrawn prior to enrollment. | Enrollment / accrual |
| NCT01148966 | Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors | Phase 1 | terminated | Jun 23, 2010 | University of Washington | not stated | Not stated |
| NCT02025231 | Image Guided Reirradiation of High-grade Glioma | Phase 1 / Phase 2 | terminated | Dec 31, 2013 | Rigshospitalet, Denmark | Slow accrual | Enrollment / accrual |
| NCT02113007 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous… | Phase 2 | terminated | Apr 14, 2014 | SCRI Development Innovations, LLC | Closed early due to slow accrual. | Enrollment / accrual |
| NCT01857752 | Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System… | Phase 2 | terminated | May 20, 2013 | Stanford University | accrual | Enrollment / accrual |
| NCT02394665 | Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma | Phase 2 | terminated | Mar 20, 2015 | University of Miami | Lack of Accrual/Enrollment | Enrollment / accrual |
| NCT02841332 | Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent…(IMAGLIO) | N/A | terminated | Jul 22, 2016 | University Hospital, Toulouse | lack of recruitment | Enrollment / accrual |
| NCT00473408 | The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in…(Gliomstudien) | — | terminated | May 15, 2007 | Haukeland University Hospital | Moved to another country, not possible to recruit from abroad. | Enrollment / accrual |
| NCT02655432 | Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population(POPH) | — | withdrawn | Jan 14, 2016 | Université de Montréal | waiting for ethic board approval | Other (stated, no rule matched) |
| NCT02371031 | FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas | Phase 1 | terminated | Feb 25, 2015 | Washington University School of Medicine | Funding source for study ended. | Funding |
| NCT01113463 | TPI 287 in Patients With Recurrent Glioblastoma Multiforme | Phase 2 | terminated | Apr 30, 2010 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT00574964 | Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme(Temodar) | Phase 2 | terminated | Dec 17, 2007 | University of Iowa | PI left the institution. | Investigator |
| NCT02047747 | A Phase II Study of Dacomitinib in Progressive Brain Metastases | Phase 2 | terminated | Jan 28, 2014 | David Piccioni, M.D., Ph.D | slow enrollment | Enrollment / accrual |
| NCT02370563 | PET Imaging of Intracranial Cancers With 18F-FSPG | Phase 1 | terminated | Feb 25, 2015 | Lantheus Biosciences Ltd. | Business decision | Sponsor / business decision |
| NCT01105702 | Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma | Phase 2 | terminated | Apr 16, 2010 | NYU Langone Health | Due to slow accrual | Enrollment / accrual |
| NCT01989052 | Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma | Phase 1 | terminated | Nov 20, 2013 | Annick Desjardins | This study was terminated early due to funding issues prior to completion of phase I | Funding |
| NCT01393769 | Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in… | Phase 2 | terminated | Jul 13, 2011 | Hospital Sant Joan de Deu | Only 5 subjects could be enrolled. Sample of 25 pat. not be achieved (rare disease). | Enrollment / accrual |
| NCT01163539 | Cyberknife Radiosurgery and Quality of Life | — | terminated | Jul 15, 2010 | Stanford University | not stated | Not stated |
| NCT02060955 | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured… | Phase 2 | terminated | Feb 12, 2014 | CytoVac A/S | Substantial design modifications required. | Other (stated, no rule matched) |
| NCT02031965 | Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade… | Phase 1 | terminated | Jan 9, 2014 | Pediatric Brain Tumor Consortium | not stated | Not stated |
| NCT01445691 | More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery | Phase 2 | withdrawn | Oct 4, 2011 | Constantinos Hadjipanayis | not stated | Not stated |
| NCT01499251 | Clinical Study on the Safety and Tolerability of Macitentan in Combination With… | Phase 1 | terminated | Dec 26, 2011 | Actelion | Results did not clearly support continuing development in recurrent GBM | Other (stated, no rule matched) |
| NCT01351519 | A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of… | Phase 2 | terminated | May 11, 2011 | MultiCare Health System Research Institute | Limited staff available for enrollment and limited availability of drug | Enrollment / accrual |
| NCT01830101 | A Phase III Study of Re-Irradiation in Recurrent Glioblastoma | Phase 3 | withdrawn | Apr 12, 2013 | AHS Cancer Control Alberta | This study will not be proceeding due to lack of funding from anticipated sources | Funding |
| NCT01249105 | MK-2206 for Recurrent Malignant Glioma | Phase 2 | withdrawn | Nov 29, 2010 | Dana-Farber Cancer Institute | Merck (supplier of study drug \& funding) has undergone a large reprioritization, in which they had… | Funding |
| NCT01756729 | Post-approval Study of NovoTTF-100A in Recurrent GBM Patients | Phase 4 | terminated | Dec 27, 2012 | NovoCure Ltd. | Amendment of Study Protocol | Other (stated, no rule matched) |
| NCT00703859 | Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly… | Phase 1 | withdrawn | Jun 24, 2008 | AHS Cancer Control Alberta | not stated | Not stated |
| NCT01954030 | Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure | Phase 1 | terminated | Oct 1, 2013 | Annick Desjardins | Study terminated early due to funding reasons prior to completing Phase 1 | Funding |
| NCT02521090 | EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory… | Phase 1 / Phase 2 | withdrawn | Aug 13, 2015 | Barbara Ann Karmanos Cancer Institute | Due to lack of funding and a primary co-investigator of the trial leaving the institution. | Investigator |
| NCT01189240 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant… | Phase 1 / Phase 2 | terminated | Aug 26, 2010 | National Cancer Institute (NCI) | Company decided to stop development of drug - 7/31/12 | Sponsor / business decision |
| NCT01260467 | Memantine for Recurrent Glioblastoma | Phase 2 | terminated | Dec 15, 2010 | University of Rochester | not stated | Not stated |
| NCT00003273 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With… | Phase 2 | withdrawn | Jan 27, 2003 | NYU Langone Health | not stated | Not stated |
| NCT02599090 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or… | Phase 2 | withdrawn | Nov 6, 2015 | M.D. Anderson Cancer Center | Multi phase study did not progress to Phase II. Phase I registered as NCT00734526. | Other (stated, no rule matched) |
| NCT01778530 | TRC105 for Recurrent Glioblastoma | Phase 2 | terminated | Jan 29, 2013 | National Cancer Institute (NCI) | Study was terminated due to poor accrual. | Enrollment / accrual |
| NCT00923117 | Sunitinib to Treat Recurrent Brain Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | The study was terminated based on results of an interim analysis for futility. | Efficacy / futility |
| NCT01898273 | Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent… | Phase 2 | terminated | Jul 12, 2013 | Cellectar Biosciences, Inc. | not stated | Not stated |
| NCT01558960 | Intravitreal Injections of Melphalan for Retinoblastoma | N/A | terminated | Mar 20, 2012 | Hadassah Medical Organization | Sufficient findings to draw conclusions | Other (stated, no rule matched) |
| NCT01227434 | A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma(PD0332991) | Phase 2 | terminated | Oct 25, 2010 | University of California, San Francisco | not stated | Not stated |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | Phase 1 / Phase 2 | withdrawn | Aug 3, 2010 | Hadassah Medical Organization | not stated | Not stated |
| NCT01861990 | Valproic Acid in Childhood Progressive Brain Tumors | Phase 1 | withdrawn | May 24, 2013 | Medical University of South Carolina | Feasibility of the trial was proven to be absent. | Other (stated, no rule matched) |
| NCT01711580 | Re-irradiation of High Grade Gliomas: a Quality of Life Study | — | withdrawn | Oct 22, 2012 | Maastricht Radiation Oncology | Another study was commenced for this patient group | Other (stated, no rule matched) |
| NCT01122888 | Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or… | Phase 1 | terminated | May 13, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01317212 | Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma… | Phase 1 | withdrawn | Mar 17, 2011 | North Bristol NHS Trust | Sufficient funding could not be secured for the study | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 13, 2017source: clinicaltrials